Dyadic 10-Q: Going Concern Reaffirmed, Cash Funds Operations Only ~7 Months
DYAI is trading near its 52-week low of $0.315 (3.8% above the low).
Summary
Dyadic's Q3 10-Q reaffirms substantial doubt about going concern: $4.57 million of unrestricted cash covers only about seven months, and a lock-up through December 17, 2026 plus an expired shelf block new equity sales. Q3 revenue fell 61.4% to $449,101.
Key Events · Earnings and Guidance · DYAI
-
Going Concern Doubt Reaffirmed
Management concluded substantial doubt exists about the ability to continue as a going concern within one year of the November 13, 2026 issuance date, and said the August 2026 offering proceeds do not alleviate that doubt.
-
Cash Runway Roughly Seven Months
Unrestricted cash, cash equivalents and investments of $4.57 million, against average operating cash use of about $0.59 million per month, are expected to fund operations for approximately seven months — less than twelve.
-
Capital Raise Blocked Until December 17
The August 2026 offering's securities purchase agreement prohibits new equity issuance until December 17, 2026, and the Form S-3 shelf expired August 25, 2026, so the $4,238,000 ATM cannot be used; after that date baby-shelf limits apply while public float stays below $75 million.
-
Nasdaq Deficiencies, March 2027 Deadline
Nasdaq notices dated September 25, 2026 flag the $1.00 minimum bid price and $35 million market value of listed securities shortfalls, with a compliance period ending March 24, 2027; the company also fails the stockholders' equity requirement.
Analysis · DYAI · Life Sciences
The survival math is now explicit in Dyadic's Q3 10-Q: unrestricted cash, equivalents and investments of $4.57 million are expected to fund operations for roughly seven months, well short of the twelve-month going-concern window, and management says the August 2026 offering proceeds do not alleviate the doubt. Selling stock to plug the gap is not an option — the August offering's securities purchase agreement bars new equity issuance until December 17, 2026, and the Form S-3 shelf expired August 25, 2026, leaving the ATM unusable. Layered on top are Nasdaq bid-price and market-value deficiencies with a March 24, 2027 compliance deadline and $5.09 million of 8% convertible notes maturing December 31, 2027, $2.09 million of which is held by CEO Mark Emalfarb's family trusts. Revenue fell 61.4% to $449,101 in the quarter as grant and collaboration work wound down, so the first direct product sales are not yet close to covering the roughly $0.59 million monthly cash burn.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYAI was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.32 to $1.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.